Literature DB >> 27733618

Insulin Treatment Prevents Neuroinflammation and Neuronal Injury with Restored Neurobehavioral Function in Models of HIV/AIDS Neurodegeneration.

Manmeet K Mamik1, Eugene L Asahchop1, Wing F Chan1, Yu Zhu1, William G Branton1, Brienne A McKenzie2, Eric A Cohen3, Christopher Power4.   

Abstract

HIV-1 infection of the brain causes the neurodegenerative syndrome HIV-associated neurocognitive disorders (HAND), for which there is no specific treatment. Herein, we investigated the actions of insulin using ex vivo and in vivo models of HAND. Increased neuroinflammatory gene expression was observed in brains from patients with HIV/AIDS. The insulin receptor was detected on both neurons and glia, but its expression was unaffected by HIV-1 infection. Insulin treatment of HIV-infected primary human microglia suppressed supernatant HIV-1 p24 levels, reduced CXCL10 and IL-6 transcript levels, and induced peroxisome proliferator-activated receptor gamma (PPAR-γ) expression. Insulin treatment of primary human neurons prevented HIV-1 Vpr-mediated cell process retraction and death. In feline immunodeficiency virus (FIV) infected cats, daily intranasal insulin treatment (20.0 IU/200 μl for 6 weeks) reduced CXCL10, IL-6, and FIV RNA detection in brain, although PPAR-γ in glia was increased compared with PBS-treated FIV+ control animals. These molecular changes were accompanied by diminished glial activation in cerebral cortex and white matter of insulin-treated FIV+ animals, with associated preservation of cortical neurons. Neuronal counts in parietal cortex, striatum, and hippocampus were higher in the FIV+/insulin-treated group compared with the FIV+/PBS-treated group. Moreover, intranasal insulin treatment improved neurobehavioral performance, including both memory and motor functions, in FIV+ animals. Therefore, insulin exerted ex vivo and in vivo antiviral, anti-inflammatory, and neuroprotective effects in models of HAND, representing a new therapeutic option for patients with inflammatory or infectious neurodegenerative disorders including HAND. SIGNIFICANCE STATEMENT: HIV-associated neurocognitive disorders (HAND) represent a spectrum disorder of neurocognitive dysfunctions resulting from HIV-1 infection. Although the exact mechanisms causing HAND are unknown, productive HIV-1 infection in the brain with associated neuroinflammation is a potential pathogenic mechanism resulting in neuronal damage and death. We report that, in HIV-infected microglia cultures, insulin treatment led to reduced viral replication and inflammatory gene expression. In addition, intranasal insulin treatment of experimentally feline immunodeficiency virus-infected animals resulted in improved motor and memory performances. We show that insulin restored expression of the nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR-γ), which is suppressed by HIV-1 replication. Our findings indicate a unique function for insulin in improving neurological outcomes in lentiviral infections, implicating insulin as a therapeutic intervention for HAND.
Copyright © 2016 the authors 0270-6474/16/3610683-13$15.00/0.

Entities:  

Keywords:  FIV; HIV-1; insulin; microglia; neuropathology; neurotoxicity

Mesh:

Substances:

Year:  2016        PMID: 27733618      PMCID: PMC6601935          DOI: 10.1523/JNEUROSCI.1287-16.2016

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  27 in total

1.  HIV-associated sensory polyneuropathy and neuronal injury are associated with miRNA-455-3p induction.

Authors:  Eugene L Asahchop; William G Branton; Anand Krishnan; Patricia A Chen; Dong Yang; Linglong Kong; Douglas W Zochodne; Bruce J Brew; M John Gill; Christopher Power
Journal:  JCI Insight       Date:  2018-12-06

Review 2.  HIV-1 infection alters energy metabolism in the brain: Contributions to HIV-associated neurocognitive disorders.

Authors:  Bianca Cotto; Kalimuthusamy Natarajanseenivasan; Dianne Langford
Journal:  Prog Neurobiol       Date:  2019-05-18       Impact factor: 11.685

Review 3.  Current and Future Therapeutic Strategies for Lentiviral Eradication from Macrophage Reservoirs.

Authors:  Tiffany A Peterson; Andrew G MacLean
Journal:  J Neuroimmune Pharmacol       Date:  2018-10-13       Impact factor: 4.147

4.  Evaluation of neuroprotective effects of insulin on immuno-inflammatory and systemic disorders induced by kaliotoxin, a Kv1.3 channel blocker.

Authors:  Zahida Taibi-Djennah; Marie-France Martin-Eauclaire; Fatima Laraba-Djebari
Journal:  Inflamm Res       Date:  2018-08-06       Impact factor: 4.575

5.  Global HIV neurology: a comprehensive review.

Authors:  Kiran T Thakur; Alexandra Boubour; Deanna Saylor; Mitashee Das; David R Bearden; Gretchen L Birbeck
Journal:  AIDS       Date:  2019-02-01       Impact factor: 4.177

Review 6.  Neurologic Complications of Human Immunodeficiency Virus Infection.

Authors:  Deanna Saylor
Journal:  Continuum (Minneap Minn)       Date:  2018-10

Review 7.  Neurologic disease in feline immunodeficiency virus infection: disease mechanisms and therapeutic interventions for NeuroAIDS.

Authors:  Christopher Power
Journal:  J Neurovirol       Date:  2017-12-15       Impact factor: 2.643

Review 8.  Insulin Signaling as a Therapeutic Target in Glaucomatous Neurodegeneration.

Authors:  Sara Al Hussein Al Awamlh; Lauren K Wareham; Michael L Risner; David J Calkins
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

9.  Infection of Glia by Human Pegivirus Suppresses Peroxisomal and Antiviral Signaling Pathways.

Authors:  M A L Doan; A Roczkowsky; M Smith; G Blevins; F K H van Landeghem; B B Gelman; W G Branton; J T Stapleton; T C Hobman; C Power
Journal:  J Virol       Date:  2021-09-15       Impact factor: 5.103

10.  Caspase-1 inhibition prevents glial inflammasome activation and pyroptosis in models of multiple sclerosis.

Authors:  Brienne A McKenzie; Manmeet K Mamik; Leina B Saito; Roobina Boghozian; Maria Chiara Monaco; Eugene O Major; Jian-Qiang Lu; William G Branton; Christopher Power
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.